Seeing Is Believing
Currently out of the existing stock ratings of Leah Cann, 2708 are a BUY (98.76%), 34 are a HOLD (1.24%).
Analyst Leah Cann works at BROOKLINE with a stock forecast success ratio of 41.67% fulfilled within 191.5 days on average. Previously, Leah Cann worked at OPPENHEIMER.
Leah Cann’s has documented 130 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MRNA, Moderna at 22-Jun-2022.
Analyst best performing recommendations are on SYRS (SYROS PHARMACEUTICALS).
The best stock recommendation documented was for MRNA (MODERNA) at 11/25/2020. The price target of $164 was fulfilled within 13 days with a profit of $54.82 (50.21%) receiving and performance score of 38.62.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
350
$63.7 (22.25%)
258
1 months 20 days ago
1/2 (50%)
$57.44 (19.63%)
325
Buy
329
$42.7 (14.91%)
300
1 months 21 days ago
6/8 (75%)
$35.42 (12.06%)
68
Buy
350
$63.7 (22.25%)
310
1 months 27 days ago
29/30 (96.67%)
$27.96 (8.68%)
508
Hold
314
$27.7 (9.68%)
272
1 months 28 days ago
8/8 (100%)
$2.98 (0.96%)
96
Buy
345
$58.7 (20.50%)
310
2 months 25 days ago
22/23 (95.65%)
$46.64 (15.63%)
610
What Year was the first public recommendation made by Leah Cann?